CJC-1295 without DAC

This is the 29-residue GHRH analogue with its four stabilising substitutions (D-Ala2, Gln8, Ala15 and Leu27) and no drug affinity complex. It is commonly called modified GRF(1-29), and its half-life is on the order of thirty minutes rather than days.

The substitutions matter. Native GHRH(1-29), sold as Sermorelin, is cleaved by DPP-4 within minutes. What these four changes buy is enough stability to produce a measurable, repeatable pulse, while keeping the pituitary and its feedback controls in the loop.

This is the form for time-course work. Where the endpoint is the shape of the growth hormone response, including amplitude, time to peak, decay and interaction with an endogenous pulse, a sustained-release form cannot answer the question and this one can.

It is also the form used in combination designs. Pairing a GHRH analogue with a ghrelin receptor agonist such as Ipamorelin, so that two receptors are activated at once and their peaks coincide, requires both to be short-acting. Published work is indexed on PubMed.

Supplied lyophilised. Without the maleimide group this form has no reactive handle to protect, which makes it more forgiving in solution than the DAC version; the main risk is ordinary peptide degradation rather than a silent chemical conversion.

Store sealed vials at -20°C, reconstitute gently, and keep solutions cold. Because the experimental value here is timing, a working solution left to degrade will flatten the very pulse the design is measuring. Solvent options are under reconstitution supplies.